Morgan Crucible Co PLC
07 December 2006
The Morgan Crucible Company plc
The Company was informed on 6th December 2006 that the Trustees of The Morgan
General Employee Benefit Trust ('the Trust') had acquired 3,000,000 Ordinary
shares in the capital of the Company at an average price of £2.505953 per share
to satisfy future obligations arising from provisional share awards made under
The Morgan Crucible Long Term Incentive Plan 2004 and share options granted
under The Morgan Crucible Executive Share Option Scheme 2004.
Following this purchase the Trust holds a total of 8,763,923 Ordinary shares
representing 2.99% of the share capital of the Company. The class of
discretionary beneficiaries for whom the Trust holds such shares consists of
employees of the Company including executive directors, Mark Robertshaw, Kevin
Dangerfield and Mark Lejman. Under the provisions of Schedule 13 of the
Companies Act 1985 these directors are deemed to be beneficially interested in
all of such shares held by the Trust.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.